{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:30:38Z","timestamp":1786987838042,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.eclinm.2021.101251","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T11:27:57Z","timestamp":1640950077000},"page":"101251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cardiovascular events and treatment of children with high risk medulloblastoma"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-2865","authenticated-orcid":false,"given":"Alessandra","family":"Cuomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Ruotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Antignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-688X","authenticated-orcid":false,"given":"Carlo G","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Passariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2021.101251_bib0001","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1126\/science.aaw4892","article-title":"Science and health for all children with cancer","volume":"363","author":"Lam","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2021.101251_bib0002","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-med-070213-054849","article-title":"Cardiovascular disease in adult survivors of childhood cancer","volume":"66","author":"Lipshultz","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.eclinm.2021.101251_bib0004","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2021.101251_bib0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2008.18.4176","article-title":"Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma","volume":"27","author":"Gandola","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0006","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/pbc.25663","article-title":"The UK experience of a treatment strategy for pediatric metastatic medulloblastoma comprising intensive induction chemotherapy, hyperfractionated accelerated radiotherapy and response directed high dose myeloablative chemotherapy or maintenance chemothera","volume":"62","author":"Vivekanandan","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2021.101251_bib0007","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","article-title":"Chemotherapy-induced cardiotoxicity in children","volume":"13","author":"Bansal","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0008","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/pbc.24540","article-title":"Evolving of therapeutic strategies for CNS-PNET","volume":"60","author":"Massimino","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2021.101251_bib0009","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"85","author":"Von Elm","year":"2007","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.eclinm.2021.101251_bib0010","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.eclinm.2021.101251_bib0011","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study group of the heart failure association and the cardio-oncology council of the European society of cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.eclinm.2021.101251_bib0012","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2011.39.8719","article-title":"Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial","volume":"30","author":"Lannering","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2014.01.022","article-title":"Hyperfractionated accelerated radiotherapy (HART) with maintenance chemotherapy for metastatic (M1\u20133) medulloblastoma \u2013 a safety\/feasibility study","volume":"111","author":"Taylor","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0014","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2006.06.4980","article-title":"Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"24","author":"Packer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/CIRCULATIONAHA.119.041403","article-title":"Increased risk of all cardiovascular disease subtypes among childhood cancer survivors","volume":"140","author":"Khanna","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2021.101251_bib0016","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000360238","article-title":"Cardiotoxicity and cardioprotection in childhood cancer","volume":"132","author":"Lipshultz","year":"2014","journal-title":"Acta Haematol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0017","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1177\/0883073815600866","article-title":"Medulloblastoma","volume":"31","author":"Millard","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0018","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2021.101251_bib0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/chd.12564","article-title":"State of the art review: chemotherapy-induced cardiotoxicity in children","volume":"13","author":"Loar","year":"2018","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.eclinm.2021.101251_bib0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.13120","article-title":"Prevention of cardiotoxicity among survivors of childhood cancer","volume":"83","author":"Hutchins","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0021","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0022","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00204-018-2170-7","article-title":"Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells","volume":"92","author":"Nemade","year":"2018","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00148581-200507030-00005","article-title":"Cardiotoxicity of cancer chemotherapy: implications for children","volume":"7","author":"Simbre","year":"2005","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.eclinm.2021.101251_bib0024","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1200\/JCO.2011.38.7852","article-title":"Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma","volume":"30","author":"Khan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101251_bib0025","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2021.101251_bib0026","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.bbmt.2016.02.017","article-title":"Clinical and Genetic determinants of cardiomyopathy risk among hematopoietic cell transplantation survivors","volume":"22","author":"Leger","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.eclinm.2021.101251_bib0027","doi-asserted-by":"crossref","first-page":"e26600","DOI":"10.1002\/pbc.26600","article-title":"Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021005320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021005320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:11:04Z","timestamp":1762888264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021005320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"alternative-id":["S2589537021005320"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101251","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular events and treatment of children with high risk medulloblastoma","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101251"}}